Clinical Trial Detail

NCT ID NCT01798485
Title A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC
Recruitment Terminated
Gender both
Phase Phase III
Variant Requirements yes
Sponsors Synta Pharmaceuticals Corp.
Indications

lung non-small cell carcinoma

Therapies

Ganetespib

Docetaxel

Age Groups: adult

Additional content available in CKB BOOST